Oppenheimer & Co. Inc. Has $74,000 Position in Omeros Co. (NASDAQ:OMER)

Oppenheimer & Co. Inc. reduced its holdings in Omeros Co. (NASDAQ:OMER) by 70.2% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 18,602 shares of the biopharmaceutical company’s stock after selling 43,902 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Omeros were worth $74,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in OMER. SPC Financial Inc. acquired a new stake in shares of Omeros in the third quarter valued at about $77,000. SG Americas Securities LLC acquired a new stake in shares of Omeros in the third quarter valued at about $80,000. Comerica Bank grew its position in shares of Omeros by 20.0% in the first quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 5,000 shares during the last quarter. BNP Paribas Financial Markets grew its position in Omeros by 75.5% during the first quarter. BNP Paribas Financial Markets now owns 30,102 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 12,951 shares in the last quarter. Finally, AQR Capital Management LLC acquired a new stake in Omeros during the second quarter worth about $105,000. 48.79% of the stock is owned by institutional investors and hedge funds.

Omeros Trading Up 41.1 %

NASDAQ OMER opened at $10.91 on Friday. The stock’s 50 day moving average is $4.50 and its two-hundred day moving average is $4.23. The company has a market capitalization of $632.23 million, a price-to-earnings ratio of -4.72 and a beta of 1.47. Omeros Co. has a 1-year low of $1.81 and a 1-year high of $10.99.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on OMER shares. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research report on Thursday, November 14th. RODMAN&RENSHAW raised Omeros to a “strong-buy” rating in a research report on Thursday, November 14th. Cantor Fitzgerald reissued a “neutral” rating on shares of Omeros in a research report on Thursday, November 14th. Rodman & Renshaw started coverage on Omeros in a research report on Thursday, November 14th. They set a “buy” rating and a $9.00 target price on the stock. Finally, StockNews.com raised Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday. Three analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.